Le Lézard
Classified in: Health, Science and technology
Subjects: Photo/Multimedia, Personnel

BioFlyte Appoints Clark Griffin as Vice President of Engineering


BioFlyte, a bioaerosol surveillance firm with a disruptive new class of fieldable biological threat collection, detection, and identification solutions, today announced the appointment of Richard C. (Clark) Griffin as Vice President of Engineering. In this role, Griffin will lead BioFlyte's engineering group, executing full lifecycle product development and commercializing its groundbreaking bioaerosol surveillance solutions.

Griffin has over four decades of experience in all aspects of product development ? from concept, technical requirements and design to integration, testing and production. He has a proven track record of successfully launching products into the automotive and defense markets and a methodical approach to engineering teams that improves outcomes. Griffin comes to BioFlyte from The Boeing Company where he led systems engineering efforts for multiple laser development programs.

Prior to Boeing, Griffin spent 15 years with Raytheon, a portion of which was recently acquired by The Vertex Company. Most recently, he served as a Program Chief Engineer/Associate Director of Systems Engineering. In that role, he was responsible for leading a cross functional team in the development, integration, and test of a vehicle upgrade package, including fire control, power distribution and all electrical subsystems. Earlier in his career he held systems engineering and technical lead roles at Delphi and Delco Electronics. Griffin also holds five patents.

"Clark brings a wealth of industry experience and engineering leadership to our growing team and business. He is well-positioned to drive our engineering efforts, including key next generation programs and new product development workstreams," said Todd Sickles, CEO of BioFlyte. "I am excited to welcome him to the management team. He brings both the enthusiasm and expertise to help BioFlyte reach its technical and commercialization milestones at this critical juncture for the company."

"I was instantly drawn to BioFlyte's mission and how the company strives to provide infrastructure protection and peace of mind to customers with its industry-first bioaerosol surveillance solutions," said Clark Griffin. "I'm thrilled about the opportunity to lead an engineering team toward commercializing a product with a great deal of potential to transform critical infrastructure protection."

To learn more about BioFlyte, please visit bioflyte.com.

About BioFlyte
BioFlyte is a bioaerosol surveillance company that is commercializing a revolutionary new class of fieldable biological contamination sampling, detection, and identification solutions. The firm's current market focus is critical infrastructure protection and mail screening in both the government and commercial sectors. For more information about BioFlyte and its products, please visit bioflyte.com.


These press releases may also interest you

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...

3 jui 2024
YOUR LEGAL RIGHTS MAY BE AFFECTED There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...

3 jui 2024
In a landmark event signaling its ambitious foray into the biopharmaceutical sector, LOTTE BIOLOGICS, under the leadership of CEO Richard W. Lee, held a groundbreaking ceremony for its inaugural plant at the Songdo Bio Campus in Incheon International...

3 jui 2024
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for hematological malignancies, announced today that on July 2, 2024, in relation to...

3 jui 2024
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal...



News published on and distributed by: